Noorda Eva M, Takkenberg Bart, Vrouenraets Bart C, Nieweg Omgo E, van Geel Bert N, Eggermont Alexander M M, Hart Guus A M, Kroon Bin B R
Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. e.noorda@nki.
Ann Surg Oncol. 2004 May;11(5):491-9. doi: 10.1245/ASO.2004.04.032. Epub 2004 Apr 12.
The influence of isolated limb perfusion (ILP) on the limb recurrence-free interval (LRFI) and the number of lesions per recurrence was studied for patients with frequently recurring regional in-transit metastases previously managed by excisional surgery.
All 43 patients who had their first ILP for a third or further limb recurrence were selected from our computer database of 451 patients who underwent therapeutic ILP for recurrent extremity melanoma in our centers. Eighteen patients had resectable and 25 had locally unresectable lesions at the time of ILP. The patients had a total of 269 intervals between treatment of their primary melanoma and last recurrence or last follow-up. Median follow-up was 35 months (interquartile range, 14-64 months).
The median LRFI decreases over time from primary melanoma to the third or further recurrence for which ILP was performed (P < 0.001). The median LRFI is 4.7 times longer (95% confidence interval [CI], 2.8-7.9; P < 0.001) after ILP in comparison with the last interval before ILP. Patients with resectable lesions have a median LRFI that is 5.9 times longer (95% CI, 2.7-13; P < 0.001). In all patients, the number of lesions increases by 22% per recurrence number (95% CI, 10%-35%; P = 0.02). At the same recurrence number, patients before ILP have a 2.6-fold higher (95% CI, 1.6-4.5) mean number of lesions than do patients after ILP (P < 0.001).
ILP lengthens the LRFI and decreases the number of lesions per recurrence significantly in patients with repeatedly recurrent limb melanoma. Therefore, ILP could be a valuable adjunct to excisional surgery for in-transit metastases in these patients whose LRFIs tend to shorten over time.
对于先前接受过切除手术治疗且区域内转移灶频繁复发的患者,研究了孤立肢体灌注(ILP)对肢体无复发生存期(LRFI)及每次复发时病灶数量的影响。
从我们中心接受复发性肢体黑色素瘤治疗性ILP的451例患者的计算机数据库中,选取了43例首次因第三次或更多次肢体复发而接受ILP的患者。18例患者在接受ILP时病灶可切除,25例患者病灶局部不可切除。这些患者在原发性黑色素瘤治疗至最后一次复发或最后一次随访之间共有269个间期。中位随访时间为35个月(四分位间距,14 - 64个月)。
从原发性黑色素瘤到进行ILP的第三次或更多次复发,LRFI的中位数随时间下降(P < 0.001)。与ILP前的最后一个间期相比,ILP后的LRFI中位数延长了4.7倍(95%置信区间[CI],2.8 - 7.9;P < 0.001)。病灶可切除的患者LRFI中位数延长了5.9倍(95% CI,2.7 - 13;P < 0.001)。在所有患者中,每次复发时病灶数量增加22%(95% CI,10% - 35%;P = 0.02)。在相同的复发次数时,ILP前的患者平均病灶数量比ILP后的患者高2.6倍(95% CI,1.6 - 4.5)(P < 0.001)。
对于肢体黑色素瘤反复复发的患者,ILP可显著延长LRFI并减少每次复发时的病灶数量。因此,对于这些LRFI往往随时间缩短的患者,ILP可能是切除手术治疗区域内转移灶的一种有价值的辅助手段。